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SARS-CoV 2 firstly emerged in China on December 2019 and it was spreading rapidly across the world 
until now. At this time, there is no vaccine or medication approved by the FDA. However, there are some 
FDA approved medicines for treating other diseases that can be used for Covid-19 based on tests. This 
review focuses on therapy efficacy, work mechanism, pharmacokinetic profile, safety, and future 
perspective. Article review related to therapy on Covid-19 patients, particularly antiviral therapy which 
was the combination of lopinavir and ritonavir, chloroquine, hydroxychloroquine, remdesivir, and 
favipiravir. The reviewed relevant articles were observational study, in vitro test, case report, and clinical 
test. A total of 13 articles met the requirement, 9 articles discussed the result of therapy during the 
medication of COVID-19 patients, 2 reports of in vitro test, and 2 results of clinical trials. From several 
studies that had been conducted, remdesivir, combination of lopinavir and ritonavir, as well as favipiravir 
showed benefits in various clinical studies on Covid-19 patients. Meanwhile, chloroquine and 
hydroxychloroquine showed limited effects and did not affect the decrease of mortality.  
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Coronavirus (Covid-19) caused by acute 
respiratory syndrome (SARS-CoV-2) is a single 
chain RNA virus whose genome encodes 
structural proteins, non-structural proteins, and 
accessory proteins [1]. It becomes a global 
concern and health problem since December 
2019. Until October 2020, the World Health 
Organization (WHO) reported that coronavirus 
Journal of Tropical Pharmacy and Chemistry 
Effectiveness of Antiviral Drugs as Covid-19 Therapy  
 
 
J. Trop. Pharm. Chem. 2021. Vol 5. No. 3.   
p-ISSN: 2087-7099; e-ISSN: 2407-6090 
272 
had been spreading to 216 countries and 
infecting 36.9 million people with 1.06 million 
deaths confirmed around the world. Meanwhile, 
27.7 million patients had recovered from the 
total affected population [2]. 
Even though the number of patients keeps 
increasing, there are no approved-FDA drugs for 
COVID-19. The treatment for each individual is 
only based on the occurring symptoms and 
when it worsens, organ supporting tools are 
used [3]. Some medications based on previous 
experience with other viruses such as malaria, 
ebola, cholera are suggested and implemented 
for controlling COVID-19. After SARS outbreak 
in 2003, screening and identification were 
conducted on approved drugs i.e. lopinavir 
(inhibitor protease type 1 HIV) which has SARS-
CoV inhibitor properties in vitro and combined 
with Ritonavir to increase the half-life of plasma 
through cytochrome P450 inhibition [4]. 
Until now, effective vaccines or antiviral 
agents specified for SARS-CoV-2 has not been 
approved yet. Therefore, the management of 
Covid-19 patients is focusing mainly on 
supportive treatment and symptomatic 
medication. The collaborative solution suggests 
clinical trials for treating Covid-19 and 
developing Covid-19 vaccines by researchers 
from some countries. There is no effective 
medication confirmed for Covid-19, however, 
the researchers attempt to develop antiviral 
strategies for COVID-19. This review describes 
the recent evidence on therapies that are 
significantly proposed or had been 
experimentally tested for COVID-19. 
 
2. Experimental section  
Searching for literature was carried out by 
collecting the data from January 2020-October 
2020 using PubMed, Google Scholar, and 
Science Direct. The keywords were “Treatment 
for COVID-19”, “Anti-viral drugs, Antimalarial 
drugs for COVID-19", or “COVID-19” along with 
the name of each drug under study, that were 
the combination of lopinavir and ritonavir, 
chloroquine, hydroxychloroquine, remdesivir, 
and favipiravir. The reviewed relevant articles 
were observational study, in vitro test, case 
report, and clinical trial. Moreover, the studies 
that were not found could be identified by 
checking the references from the selected 
articles. The inclusion criteria in choosing the 
literature were COVID-19 patients who received 
therapy with one of the drugs under study 
(combination of lopinavir and ritonavir, 
chloroquine, hydroxychloroquine, remdesivir, 
and favipiravir) with or without combination 
with other drugs, the number of research 
sample >100 and in vitro test or related 
laboratory tests. The exclusion criteria were 
article duplication, incomplete article, literature 
review, the number of sample <100, and 
therapy with other than the specified drugs. 
 
3. Results and Discussion 
Overall, a total of 13 articles met the 
requirements. 9 articles discussed the results of 
therapy given during the treatment of COVID-19 
patients, 2 reports on in vitro test, and 2 results 
of clinical trial. The results of literature study 
are listed in Table 3.  
This analysis was conducted based on 
controlled randomized studies published for 
Covid-19 medication, clinical trials that had 
been successfully conducted, as well as several 
agents based on in vitro tests or observational 
study. At this moment, there are about 3500 
researches recorded as Covid-19 clinical trials 
that can be accessed in the database of Clinical 
Trials.gov and through WHO international 
clinical trial registration platform [5]. The 
urgent need in finding Covid-19 medications 
resulted in two proposed approaches: 
administration of approved drugs (initially 
introduced for other diseases) with high safety 
profile and shows promising in vitro results to 
SARS-CoV, MERS-CoV, and SARS-CoV-2 
combined with convalescent plasma, and the 
second one is developing new antiviral agents 
and vaccines to protect against SARS-Cov-2 [6]. 
Some drugs that are frequently used and 
discussed in this review are chloroquine, 
hydroxychloroquine, lopinavir/ritonavir, 
remdesivir, and favipiravir. Rapid mechanism of 
action and pharmacokinetic profiles are 
presented in Table 1 and Table 2. 
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Table 1 Mechanism of Action [7] 
Group Drug Mechanism of Action 
Working when virus enter Lopinavir/Ritonavir 3–chymotrypsin-like protease inhibitor 
Chloroquine Increasing pH endosome, and disrupting glycosylation ofACE-2 receptor 
Hydroxychloroquine 
Working during virus 
replication 
Remdesivir Analog adenosine nucleotide, prodrug, inhibiting RdRp activities 




Table 2 Pharmacokinetic Profile [7],[8] 





Fast absorption and 
almost perfect  
Incomplete and varied 
(~70%) 




Vd : 200 L/kg 
Protein binding: ~55% 
Vd : 153-1650 L 
Protein binding: ~40% 
Protein binding : 
98%-99% 
Distributed in free 
fraction 12.1% 













especially by aldehyde 
oxidase (AO) and partly 
by xanthin oxidase (XO) 
Excretion 
Urine : ~70%, ~35% 
shape did not change  
Urine : 15-25% Feces : 20% did 
not change  
Urine : 2.2% did 
not change  
Feces : 18% 
Urine : 74%  shape 




6-60 days (average 20 
days) 
Blood : 172.3 hours-50 days  
Plasma : 32 -123.5 days 




Table 3 Literature Studies on Therapy to Covid-19 Patients 
No. Research 
Design  
Research Sample Inclusion Criteria Intervention Result Refernce  
1.  In Vitro  Using infected Vero 
cells  
Isolation of SARS-
CoV-2 virus strain 
spread in Vero cells 
Hydroxychloroquine 
(400 mg/12 hours 
followed by 200 
mg/12 hours for 4 
days) 
Vero cell test showed that in vitro 
hydroxychloroquine was more potent 
than chloroquine and 3x more potent 
when given at a dose of 500mg/12 
hours. 
[9] 
2.  In Vitro  Using infected Vero 
E6 cells 




Remdesivir and chloroquine were 
effective to control Covid-19 infection in 
vitro 
[10] 
3.  Randomized 
control open- 
label trial 
99 people received 





2 infection, oxygen 
saturation 94% or 
less  
Lopinavir (400 
mg/12 hours) and 
Ritonavir (100 
mg/12 hours) 
The average time required to improve 
patients’ clinical condition was 15 days 
compared to 16 days for the standard 
therapy group. There was no significant 
difference in the time required for 
clinical improvement between the two 
groups (lopinavir, ritonavir, and 
standard therapy) 
[11] 







Patient age ≥18 
years-old, early 





followed by 600 
mg/12 hours) and 
Arbidol (200 mg/ 8 
hours) 
Improvement in clinical conditions on 
day 7 was not significantly different 
between the two groups. Favipiravir 
significantly increased latency to recover 
from fever and cough. 
[12] 









Adult patients with 
Covid-19 with 
involvement of  lower 
respiratory tract  
Remdesivir IV 200 
mg loading dose on 
the first day, followed 
by 100 mg a day to 9 
days 
Remdesivir had recovery time at an 
average of 11 days, mortality at day 14 
was 7.1%, and severe adverse events in 
114 of 541 patients (21.1%). Compared 
to placebo, the average recovery was 15 
days, 11.9% mortality, and severe 




Effectiveness of Antiviral Drugs as Covid-19 Therapy  
 
 
J. Trop. Pharm. Chem. 2021. Vol 5. No. 3.   
p-ISSN: 2087-7099; e-ISSN: 2407-6090 
274 
Table 3 ………. 
No. Research 
Design  
Research Sample Inclusion Criteria Intervention Result Reference 








IV, and 79 patients 
received placebo 
infusion 
Patients ≥18 years-old 
with symptom onset of 
12 days or less, oxygen 
saturation of 94% or 
less, and radiologically 
confirmed pneumonia. 
Conducted at 10 
hospitals in Hubei, 
China. 
Remdesivir IV 
200 mg D1, 
followed by 100 
mg D2-D10 in a 
daily single 
infusion 
Remdesivir group had a shorter time to 
clinical improvement although it was not 
statistically significant. For adult 
patients with severe Covid-19, 
Remdesivir was not associated with 
statistically significant clinical benefits. 
[14] 





for 10 days, 
199 patients 
received remdesivir 
















Remdesivir treatment for 10 days did 
not have a statistically significant 
difference in clinical status compared to 
standard therapy. 
Remdesivir treatment for 5 days had 
statistically significant differences with 
standard therapy but was not clinically 
important. 
[15] 
8.  Randomized, 
open label, 
phase 3 trial 
197 patients 
received remdesivir 
for 10 days, 
200 patients 
received remdesivir 
for 5 days 










Did not show significant differences in 
remdesivir administration for 5 days or 
10 days.  
[16] 
9.  Observational 
study 
811 patients Patients with 
confirmed SARS-CoV-2 
treated in hospital 
HCQ 600mg 2x a 
day D1, and 
400mg for 5 days 
HCQ did not affect intubation or 
mortality in patients with COVID-19 
[17] 








Adults with symptoms, 
not hospitalized, 
laboratory-confirmed 
Covid-19 or at high 
risk of exposure to 
Covid-19 within 4 days 
of symptom onset 
HCQ 800mg/day 
followed by 
600mg within 6-8 
hours, then 
600mg/day for 4 
days 
HCQ did not reduce the severity of 
symptoms in minor COVID-19 
outpatient 
[18] 











symptoms <5 days 
HCQ 800mg/day  
and 400mg/day 
for 6 days 
HCQ did not show benefits in patients 
with mild Covid-19  
[19] 












received other drugs  
Age ≥18 years-old, 
treated in Hospital for 
minimum 48 hours 
HCQ 400mg 2x a 
day D1, 200mg 2x 
a day D2-D5 
Azitromisin 
500mg 1x a day, 
250mg/day for 4 
days. 
HCQ only or with azithromycin in 
patients with COVID-19 was associated 
with mortality decreases related to 
COVID-19. 
[20] 











received other drugs 
Laboratory confirmed 
Covid-19 and had been 
hospitalized for 24 
hours 
Not specified HCQ with or without azithromycin was 
not significantly different related to 
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Protease is an essential enzyme for the 
production and maturation of the viral genome. 
The main antiviral effect of protease inhibitors 
is the prevention of viral replication, thus 
limiting spread into host cells. The therapeutic 
reason for using LPV/r arises from an in vitro 
study showing inhibition of the 3-chymotrypsin 
protease found in the coronavirus. [22]. 
Lopinavir is formulated with ritonavir (LPV/r) 
to increase pharmacokinetic activities and LPV 
half-life through CYP450 inhibition. 
Structurally, the two compounds are the 
derivative 1,6-diphenyl-4-hydroxy-2,5-
diaminohexane whose aminohexane group 
contains side chains with various substituted 
cyclic groups such as phenoxy/ 3,5-diazinan 
(Lopinavir) or 1,3-thiazole [6]. 
Lopinavir/ritonavir is available in single 
tablets with a dose of 400/100 mg or 200/100 
mg. For COVID-19, the dosage is 400 mg/100 mg 
orally twice daily for 14 days. Lower doses of 
200/100 mg twice a day can be considered if the 
side effects are within the threshold of 
tolerability, given that lower doses may not 
substantially reduce toxicity. Ritonavir is a 
strong CYP3A4 inhibitor which is the main 
enzyme for metabolism and elimination of many 
drugs, so special attention needs to be paid if it 
is used in elderly patients with COVID-19 who 
have comorbidities and are receiving 
polypharmacy therapy because interactions can 
occur between drugs. [22]. 
Treatment with LPV/r can cause 
intolerable gastrointestinal toxicity, although 
administration with food may improve the 
severity of these symptoms. 24% of patients had 
diarrhea and improved within 2 weeks. In 
studies for usage in SARS found an elevation in 
serum amylase and liver enzymes; therefore, 
routine monitoring of liver function tests is 
necessary as well as supportive care with 
antiemetics and antimotility should be 
considered [22]. According to the Infectious 
Diseases Society of America (IDSA), the clinical 
data published on LPV/r regarding its efficacy 
against COVID-19 is insufficient to recommend 
this drug as a therapy, only in the context of 
clinical trials. [23]. 
3.2 Chloroquine Phosphate and 
Hydroxychloroquine 
Regarding the activities of SARS CoV-2, the 
mechanism of action of these two drugs is 
categorized into: first, inhibition of 
enzymes/processes in viruses (DNA virus 
and/or RNA polymerase), glycosylation of viral 
proteins, transport of new virus particles, and 
release of viruses. The second is inhibiting ACE2 
cellular receptor, acidifying the cell membrane 
surface so it inhibits viral fusion, and 
immunomodulating the release of cytokines. 
Structurally, these two compounds are 7-
chloro-quinoline derivatives with the 
novaldiamine substituent in the fourth position, 
where HCQ has an additional hydroxyl group at 
the end of the structure. The addition of 
hydroxyl group increases hydrosolubility, 
flexibility, and polarity as well as decreases in 
polarity compared to CQ [6]. 
Chloroquine is formulated as a tablet in the 
form of phosphate salt for oral administration. 
In treating COVID-19, experts recommend 
chloroquine phosphate tablets at a dose of 500 
mg orally twice/day for 10 days [22]. The 
recommended therapeutic dose of HCQ from 
several Covid-19 treatment guidelines is 
800mg/day on day 1, followed by 400mg/day 
for 4 days [24], [22]. The most common side 
effects are gastrointestinal intolerance such as 
nausea, vomiting and stomach cramps, 
prolonged QT interval (after short-term 
treatment), and acute toxicity in the form of 
cardiomyopathy, neuropathy, or myopathy. 
Retinopathy occurs when using 
hydroxychloroquine and chloroquine especially 
in high doses and over a long period. [25]. 
There have been reports of hypoglycemia 
progressing to loss of consciousness when used 
in patients with diabetes history and in 
concomitant use with antidiabetic agents [6], 
[22]. A retrospective study conducted on 95 
hospitalized COVID-19 patients treated with CQ 
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showed that 23% of the patients showed 
prolonged QT interval [26]. 
Current preclinical and clinical data 
regarding the use of CQ and HCQ in SARS-CoV-2 
infection are not considered robust [6], and the 
EMA does not endorse the use of chloroquine as 
a standard treatment in COVID-19 and is 
restricted to its use exclusively in clinical trials 
or through national emergency use programs 
[27]. In addition, WHO has discontinued clinical 
trials using hydroxychloroquine as a Covid-19 
therapy because it does not provide effects on 
reducing the mortality of inpatients compared 
to standard care [28]. Among hospitalized 
COVID-19 patients, IDSA guidelines recommend 
against the use of hydroxychloroquine [29]. 
3.3 Remdesivir 
Remdesivir is currently considered as the 
most promising therapy for SARS-CoV-2 
infection based on the results obtained in phase 
III clinical trial by the National Institute of 
Allergy and Infectious Diseases (NIAID) in the 
Adaptive COVID-19 Treatment Trial (ACTT) [6]. 
RDV exhibits antiviral activity against other 
single-chain RNA viruses such as filovirus, 
pneumovirus, paramyxovirus, and MERS-CoV 
and SARS-CoV coronaviruses. Remdesivir is a 
monophosphate nucleotide analog product (GS-
441524) which is metabolized rapidly in cells 
and tissues into its active form of adenosine 
triphosphate (GS-443902), which inhibits RNA-
dependent RNA polymerase (RdRp) activities in 
the viral infection cycle. Another potential 
mechanism is causing lethal mutagenesis and 
chain breakdown [30],[31]. 
Structurally, RDV is a nucleoside analog 
which is very similar to AMP (adenosine 
monophosphate), an important structural 
difference occurs in both the nucleobase region, 
where the purine ring is replaced by pyrrolo 
[2,1-f] [1,2,4] triazine, and the ribose region 
where the cyanide group is in the fifth position. 
Moreover, the phosphate group is attached to 
the phenoxy group and α-Alanine-2-ethyl-butyl 
ester, which increases the lipofility of the 
molecule and the degree of structural flexibility. 
RDV acts as a competitive ATP (adenosine 
triphosphate) inhibitor, targeting an enzyme 
involved in viral genome replication, which is 
RNA-dependent RNA polymerase (RdRp) [6]. 
It is formulated in two pharmaceutical 
forms (5mg/ml solution and 100mg lyophilized 
powder) and is recommended to be 
administered intravenously (30-120 minutes) 
after reconstitution in 0.9% saline solution or 
glucose 5% with a therapeutic dose 200mg on 




2-carboxamide) is a pyrazine carboxamide oral 
and analog guanine derivative developed in 
Japan for treating influenza. These compounds 
work selectively and potently inhibit the RNA-
dependent RNA polymerase (RdRp) of the RNA 
virus and cause deadly RNA transversion 
mutations resulting in a non-viable viral 
phenotype. Favipiravir is metabolized into its 
active form, favipiravir ribofuranosyl-50-
triphosphate, which is metabolized in the liver 
and does not produce significant drug 
interactions, otherwise it does not affect human 
DNA polymerase subunit α, β, γ (up to 100 
μg/ml), so it does not cause toxic effects [22],[6]. 
In a clinical study conducted by National 
Clinical Research Center for contagious diseases 
in Shenzhen, two doses of 1.600mg favipiravir 
on the first day and two doses of 600mg for the 
following 13 days, in addition to the interferon-
alfa aerosol inhalation (five million units twice a 
day), resulted in faster viral clearance than the 
lopinavir/ritonavir group, with an average of 4 
days versus 11 days, as well as enhanced chest 
imaging. Randomized trials carried out for this 
drug in combination with other drugs are 
favipiravir + interferon-α, and favipiravir + 
baloxavir [7]. 
 
4. Conclusion  
Nowadays, there is still no medication or 
vaccine approved for Covid-19 pandemic that is 
striking the world to date. However, there are 
several types of medicine approved by FDA that 
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are used to treat other diseases and can be used 
for Covid-19 based on in vitro and clinical tests 
on patients infected with SARS CoV-2. It is 
known that remdesivir, combination of 
lopinavir and ritonavir, as well as favipiravir 
showed benefits in various clinical studies on 
Covid-19 patients. Meanwhile, chloroquine and 
hydroxychloroquine had limited effects and did 
not affect the decrease of mortality. 
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